These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30679796)

  • 1. Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia.
    Kollmann S; Grundschober E; Maurer B; Warsch W; Grausenburger R; Edlinger L; Huuhtanen J; Lagger S; Hennighausen L; Valent P; Decker T; Strobl B; Mueller M; Mustjoki S; Hoelbl-Kovacic A; Sexl V
    Leukemia; 2019 Jul; 33(7):1583-1597. PubMed ID: 30679796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR-ABL affects STAT5A and STAT5B differentially.
    Schaller-Schönitz M; Barzan D; Williamson AJ; Griffiths JR; Dallmann I; Battmer K; Ganser A; Whetton AD; Scherr M; Eder M
    PLoS One; 2014; 9(5):e97243. PubMed ID: 24836440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
    Wang X; Yang J; Guo G; Feng R; Chen K; Liao Y; Zhang L; Sun L; Huang S; Chen JL
    Mol Cancer; 2019 Apr; 18(1):84. PubMed ID: 30961617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymoquinone Induces Downregulation of BCR-ABL/JAK/STAT Pathway and Apoptosis in K562 Leukemia Cells.
    Al-Rawashde FA; Wan Taib WR; Ismail I; Johan MF; Al-Wajeeh AS; Al-Jamal HAN
    Asian Pac J Cancer Prev; 2021 Dec; 22(12):3959-3965. PubMed ID: 34967577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.
    Casetti L; Martin-Lannerée S; Najjar I; Plo I; Augé S; Roy L; Chomel JC; Lauret E; Turhan AG; Dusanter-Fourt I
    Cancer Res; 2013 Apr; 73(7):2052-8. PubMed ID: 23400594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction.
    Fahrenkamp D; de Leur HS; Küster A; Chatain N; Müller-Newen G
    Cell Commun Signal; 2015 Feb; 13():10. PubMed ID: 25885255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis.
    Nieborowska-Skorska M; Wasik MA; Slupianek A; Salomoni P; Kitamura T; Calabretta B; Skorski T
    J Exp Med; 1999 Apr; 189(8):1229-42. PubMed ID: 10209040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive interactions between STAP-1 and BCR-ABL influence chronic myeloid leukemia cell proliferation and survival.
    Ishiura M; Kitai Y; Kashiwakura JI; Muromoto R; Toda J; Ichii M; Oritani K; Matsuda T
    Biochem Biophys Res Commun; 2021 Jun; 556():185-191. PubMed ID: 33845308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.
    Liao Z; Gu L; Vergalli J; Mariani SA; De Dominici M; Lokareddy RK; Dagvadorj A; Purushottamachar P; McCue PA; Trabulsi E; Lallas CD; Gupta S; Ellsworth E; Blackmon S; Ertel A; Fortina P; Leiby B; Xia G; Rui H; Hoang DT; Gomella LG; Cingolani G; Njar V; Pattabiraman N; Calabretta B; Nevalainen MT
    Mol Cancer Ther; 2015 Aug; 14(8):1777-93. PubMed ID: 26026053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STAT5 signaling is required for the efficient induction and maintenance of CML in mice.
    Ye D; Wolff N; Li L; Zhang S; Ilaria RL
    Blood; 2006 Jun; 107(12):4917-25. PubMed ID: 16522816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia.
    Waight JD; Banik D; Griffiths EA; Nemeth MJ; Abrams SI
    J Biol Chem; 2014 May; 289(22):15642-52. PubMed ID: 24753251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.
    Yuan H; Wang Z; Li L; Zhang H; Modi H; Horne D; Bhatia R; Chen W
    Blood; 2012 Feb; 119(8):1904-14. PubMed ID: 22207735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia.
    Warsch W; Grundschober E; Berger A; Gille L; Cerny-Reiterer S; Tigan AS; Hoelbl-Kovacic A; Valent P; Moriggl R; Sexl V
    Oncotarget; 2012 Dec; 3(12):1669-87. PubMed ID: 23458731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
    Hantschel O; Warsch W; Eckelhart E; Kaupe I; Grebien F; Wagner KU; Superti-Furga G; Sexl V
    Nat Chem Biol; 2012 Jan; 8(3):285-93. PubMed ID: 22286129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis.
    Qiu X; Guo G; Chen K; Kashiwada M; Druker BJ; Rothman PB; Chen JL
    Neoplasia; 2012 Jun; 14(6):547-58. PubMed ID: 22787435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.
    Chatain N; Ziegler P; Fahrenkamp D; Jost E; Moriggl R; Schmitz-Van de Leur H; Müller-Newen G
    Oncogene; 2013 Aug; 32(31):3587-97. PubMed ID: 22926520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel imatinib-upregulated long noncoding RNA plays a critical role in inhibition of tumor growth induced by Abl oncogenes.
    Ma Y; Guo G; Li T; Wen F; Yang J; Chen B; Wang X; Chen JL
    Mol Cancer; 2022 Jan; 21(1):5. PubMed ID: 34980123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.
    Carlesso N; Frank DA; Griffin JD
    J Exp Med; 1996 Mar; 183(3):811-20. PubMed ID: 8642285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
    Shuai K; Halpern J; ten Hoeve J; Rao X; Sawyers CL
    Oncogene; 1996 Jul; 13(2):247-54. PubMed ID: 8710363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.
    Eiring AM; Neviani P; Santhanam R; Oaks JJ; Chang JS; Notari M; Willis W; Gambacorti-Passerini C; Volinia S; Marcucci G; Caligiuri MA; Leone GW; Perrotti D
    Blood; 2008 Jan; 111(2):816-28. PubMed ID: 17925491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.